Healthcare Prediction Markets

FDA Drug Approval & Healthcare Prediction Markets — 2026

New GLP-1 drug approval at 62%, mRNA cancer vaccine breakthrough at 38%, RFK Jr. FDA process change at 42%. Healthcare prediction markets on Polymarket and Kalshi price every major FDA and policy milestone — compare cross-venue healthcare odds in one search.

Search healthcare markets →

Top FDA & Healthcare Prediction Markets 2026

~62% · $380K/day

Will the FDA approve a new GLP-1 obesity drug (beyond Ozempic/Wegovy) in 2026?

Eli Lilly, Pfizer pipeline — high-volume FDA market

Compare venues →

~55% · $220K/day

Will Alzheimer's drug lecanemab (Leqembi) show slowing in Phase 4 trials by 2026?

Long-running disease modification market

Compare venues →

~38% · $290K/day

Will a cancer vaccine (mRNA) receive FDA approval or breakthrough designation in 2026?

Moderna/Merck mRNA cancer vaccine pipeline

Compare venues →

~42% · $340K/day

Will RFK Jr. make major changes to FDA drug approval processes by end of 2026?

Policy change market — HHS leadership

Compare venues →

~48% · $160K/day

Will US life expectancy increase above pre-COVID levels by end of 2026?

Public health recovery market

Compare venues →

Related Macro Hubs

Macro

Recession 2026

Healthcare costs affect consumer spending — recession macro connection

View recession hub →

AI

AGI 2026

AI drug discovery markets — AI-accelerated FDA pipeline

View AGI hub →

FAQ

Are there prediction markets for FDA drug approvals in 2026?

Yes. Polymarket and Kalshi both carry active FDA approval markets — GLP-1 drugs (obesity treatment pipeline), Alzheimer's disease-modifying therapies, mRNA cancer vaccines, and specific PDUFA date outcomes. The GLP-1 market is the highest-volume FDA prediction market with $380K in daily trading, reflecting the massive commercial stakes around Eli Lilly and Pfizer's pipeline.

What prediction markets exist for GLP-1 obesity drugs beyond Ozempic?

Polymarket has active markets for: FDA approval of Eli Lilly's orforglipron (oral GLP-1), FDA approval of Pfizer's danuglipron, and broader questions about new GLP-1 class approvals. With Ozempic/Wegovy already generating $15B+/year, the pipeline market is highly watched. Prediction markets price a new FDA-approved GLP-1 entrant at ~62% in 2026.

How do healthcare prediction markets work for investors?

FDA approval prediction markets function like binary event bets — they resolve YES/NO based on official FDA announcements. These markets often trade well before PDUFA (target action) dates and can price in insider-knowledge-level probability faster than sell-side analyst reports. Kalshi is particularly active for pharmaceutical regulatory milestones because of its regulatory compliance framework.

What effect will RFK Jr. have on FDA approval markets?

Robert F. Kennedy Jr. as HHS Secretary has created an active prediction market category: FDA process change markets. Prediction markets price major FDA approval process changes at ~42%, reflecting uncertainty about the scope of his influence on established agency procedures. These markets move with RFK Jr.'s public statements and any formal FDA rule proposals.